Bayer - Stop TB Partnership

Partnership Objectives

Support Stop TB Partnership in fighting MDR TB.

The mycobacterial strains in TB multiply in infected organs and destroy healthy tissue. Here, Fernando, 28, is treated with antibiotics in South Africa. The mycobacterial strains in TB multiply in infected organs and destroy healthy tissue. Here, Fernando, 28, is treated with antibiotics in South Africa. Copyright Bayer Healthcare

What are the health needs and challenges?

The current six- to eight-month standard therapy for tuberculosis (TB) is based on four drugs that were discovered more than 30 years ago and often have to be administered under the direct supervision of healthcare professionals. The long period makes consistent treatment more difficult to achieve, and the number of resistant strains of bacteria is therefore increasing. The available medicines are not effective against the multi-drug-resistant TB (MDR-TB) caused by resistant bacteria.

Description of partnership activities and how they address needs and challenges

In 2011 Bayer HealthCare Pharmaceuticals agreed with the World Health Organization (WHO) to support countries in the treatment of multidrug-resistant tuberculosis (MDR-TB) with moxifloxacin, a well-known antibiotic for the treatment of acute respiratory infection as well as other infections with an established safety record. 

The collaboration with the WHO includes the involvement in a program designed to support increased access to quality-assured second-line anti-tuberculosis which targets to increase treatment success against MDR-TB and thereby could also reduce the likelihood for further resistance development to anti tuberculosis drug.

STOP TB partnership of the WHO makes moxifloxacin available to MDR TB patients in need under specifically defined conditions of treatment programs authorized by the STOP-TB Partnership in collaboration with national TB treatment programs.

Summary of impact and forward looking information

Sixteen countries have joined the program since December 2011. A total of around 1.3 million moxifloxacin tablets were supplied to six countries (China, Georgia, Armenia, Haiti, Russia and Indonesia) in 2013. This quantity of the drug enables the treatment of a good 2,450 MDR-TB patients for the minimum treatment period of 18 months.

Partnership information

Company(ies) Bayer

Partner(s) Stop TB Partnership

Type of Partner(s) Multilaterals

Therapeutic Focus Infectious Diseases

Disease(s) Drug-Resistant Infections (AMR), Tuberculosis

Program Type(s) Availability of Treatment - Differential Pricing, Availability of Treatment - Product Donations

Targeted Population(s) Men, Patients in needs of treatment, Women

Region(s) East Asia & Pacific, Europe & Central Asia, Latin America & Caribbean, South Asia, Sub-Saharan Africa

Number of Countries 16

Country(ies) Armenia, Belarus, China, Cuba, Ecuador, Georgia, Haiti, India, Indonesia, Mexico, Peru, Philippines, Russia, South Africa, Ukraine, Venezuela

Start Date 2011

More information Bayer Healthcare

Anticipated completion date Ongoing